BID | 232.50 | ASK | 241.50 | ||
Open | 236.07 | Previous Close | 236.18 | ||
Pre-Market | - | After-Market | 238.25 | ||
- - | - -% |
Target Price | 265.56 | Analyst Rating | Moderate Buy 1.58 | |
Potential % | 11.46 | Finscreener Ranking | ★ 39.67 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★ 41.18 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 44.26 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★ 29.46 | |
Price Range Ratio 52W % | 16.41 | Earnings Rating | Strong Sell | |
Market Cap | 69.19B | Earnings Date | 9th Nov 2023 | |
Alpha | -0.00 | Standard Deviation | 0.06 | |
Beta | 0.56 |
Today's Price Range 235.34238.50 | 52W Range 228.62287.32 | 5 Year PE Ratio Range 32.50632.20 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -1.13% | ||
1 Month | -6.94% | ||
3 Months | -15.18% | ||
6 Months | -4.81% | ||
1 Year | -5.84% | ||
3 Years | -0.69% | ||
5 Years | -6.56% | ||
10 Years | 125.50% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 3.48 | |||
ROE last 12 Months | 7.45 | |||
ROA (5Y Avg) | 1.20 | |||
ROA last 12 Months | 3.43 | |||
ROC (5Y Avg) | 3.87 | |||
ROC last 12 Months | 4.85 | |||
Return on invested Capital Q | 0.85 | |||
Return on invested Capital Y | 4.93 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 7.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
44.00 | ||||
2.92 | ||||
5.17 | ||||
28.30 | ||||
-57.10 | ||||
9.17 | ||||
-6.33 | ||||
88.93 | ||||
88.78B | ||||
Forward PE | 16.72 | |||
PEG | 4.54 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.40 | ||||
1.00 | ||||
0.35 | ||||
0.64 | ||||
5.50 | ||||
Leverage Ratio | 2.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
44.90 | ||||
12.80 | ||||
24.10 | ||||
7.80 | ||||
8.21 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
13.88B | ||||
48.81 | ||||
2.12 | ||||
10.10 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.44 | ||||
3.64 | ||||
4.04 | ||||
3.27 | ||||
Payout ratio | 57.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 2.89 | 2.96 | 2.42 |
Q02 2023 | 2.75 | 2.86 | 4.00 |
Q01 2023 | 2.67 | 2.98 | 11.61 |
Q04 2022 | 2.73 | 2.75 | 0.73 |
Q03 2022 | 2.49 | 2.66 | 6.83 |
Q02 2022 | 2.98 | 3.18 | 6.71 |
Q01 2022 | 2.86 | 3.64 | 27.27 |
Q04 2021 | 2.43 | 2.59 | 6.58 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | 2.46 | -19.87 | Negative |
3/2024 QR | 3.01 | -4.75 | Negative |
9/2024 FY | 12.84 | -5.10 | Negative |
9/2025 FY | 14.28 | -4.99 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 3.42 |
Estimates Count | 10 |
EPS Growth Next 5 Years % | 9.70 |
Volume Overview | |
---|---|
Volume | 1.50M |
Shares Outstanding | 290.41K |
Shares Float | 268.33M |
Trades Count | 31.13K |
Dollar Volume | 357.01M |
Avg. Volume | 1.65M |
Avg. Weekly Volume | 1.85M |
Avg. Monthly Volume | 1.80M |
Avg. Quarterly Volume | 1.29M |
Becton Dickinson and Company (NYSE: BDX) stock closed at 236.18 per share at the end of the most recent trading day (a 0.21% change compared to the prior day closing price) with a volume of 2.85M shares and market capitalization of 69.19B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 72000 people. Becton Dickinson and Company CEO is Thomas E. Polen.
The one-year performance of Becton Dickinson and Company stock is -5.84%, while year-to-date (YTD) performance is -7.13%. BDX stock has a five-year performance of -6.56%. Its 52-week range is between 228.615 and 287.32, which gives BDX stock a 52-week price range ratio of 16.41%
Becton Dickinson and Company currently has a PE ratio of 44.00, a price-to-book (PB) ratio of 2.92, a price-to-sale (PS) ratio of 5.17, a price to cashflow ratio of 28.30, a PEG ratio of 4.54, a ROA of 3.43%, a ROC of 4.85% and a ROE of 7.45%. The company’s profit margin is 8.21%, its EBITDA margin is 24.10%, and its revenue ttm is $13.88 Billion , which makes it $48.81 revenue per share.
Of the last four earnings reports from Becton Dickinson and Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $3.42 for the next earnings report. Becton Dickinson and Company’s next earnings report date is -.
The consensus rating of Wall Street analysts for Becton Dickinson and Company is Moderate Buy (1.58), with a target price of $265.56, which is +11.46% compared to the current price. The earnings rating for Becton Dickinson and Company stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Becton Dickinson and Company has a dividend yield of 1.44% with a dividend per share of $3.64 and a payout ratio of 57.00%.
Becton Dickinson and Company has a Sell technical analysis rating based on Technical Indicators (ADX : 9.32, ATR14 : 4.19, CCI20 : -45.20, Chaikin Money Flow : -0.05, MACD : -5.24, Money Flow Index : 39.61, ROC : 0.65, RSI : 36.09, STOCH (14,3) : 59.98, STOCH RSI : 0.46, UO : 42.53, Williams %R : -40.02), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Becton Dickinson and Company in the last 12-months were: Richard Byrd (Sold 1 421 shares of value $353 261 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
CEO: Thomas E. Polen
Telephone: +1 201 847-6800
Address: 1 Becton Drive, Franklin Lakes 07417-1880, NJ, US
Number of employees: 72 000
Thu, 12 Oct 2023 05:55 GMT Becton Dickinson (BDX) Receives a Buy from DBS
- TipRanks. All rights reserved.Mon, 07 Aug 2023 09:20 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)
- TipRanks. All rights reserved.Mon, 24 Jul 2023 11:35 GMT Becton Dickinson (BDX) Gets a Buy from Bank of America Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.